Turbine Raises €20 Mn to Advance Its Cancer Cell Simulation Platform.
Turbine leverages its technology by identifying associated biomarkers and combination strategies and selecting in vitro and in vivo biological models for experimental validation. Turbine partners with biopharmaceutical companies seeking to deploy simulations to understand patients and overcome causes of resistance hindering drug development in the clinic.
See the full article on BusinessWire
